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New concepts in breast cancer genomics
and genetics
Rodrigo Goncalves1,2,5, Wayne A Warner1,2,3,5, Jingqin Luo2,4,5 and Matthew J Ellis1,2,5*
Abstract
Massively parallel DNA and RNA sequencing approaches have generated data on thousands of breast cancer
genomes. In this review, we consider progress largely from the perspective of new concepts and hypotheses raised
so far. These include challenges to the multistep model of breast carcinogenesis and the discovery of new defects
in DNA repair through sequence analysis. Issues for functional genomics include the development of strategies to
differentiate between mutations that are likely to drive carcinogenesis and bystander background mutations, as well
as the importance of mechanistic studies that examine the role of mutations in genes with roles in splicing, histone
methylation, and long non-coding RNA function. The application of genome-annotated patient-derived breast
cancer xenografts as a potentially more reliable preclinical model is also discussed. Finally, we address the challenge
of extracting medical value from genomic data. A weakness of many datasets is inadequate clinical annotation, which
hampers the establishment of links between the mutation spectra and the efficacy of drugs or disease phenotypes.
Tools such as dGene and the DGIdb are being developed to identify possible druggable mutations, but these programs
are a work in progress since extensive molecular pharmacology is required to develop successful ‘genome-forward’
clinical trials. Examples are emerging, however, including targeting HER2 in HER2 mutant breast cancer and mutant
ESR1 in ESR1 endocrine refractory luminal-type breast cancer. Finally, the integration of DNA- and RNA-based
sequencing studies with mass spectrometry-based peptide sequencing and an unbiased determination of
post-translational modifications promises a more complete view of the biochemistry of breast cancer cells and
points toward a new discovery horizon in our understanding of the pathophysiology of this complex disease.
Introduction
A decade after the first version of the human genome
was published [1], annotation efforts continue, bringing
us to the 19th revision, which is the current research
standard. Analysis of protein-coding genes and their
regulatory sequences is nearing completion, but these
functions are served by only a small fraction of the gen-
ome. The rest is more functional than once thought, en-
coding, for example, many non-protein coding RNA
genes with emerging regulatory and catalytic roles in cel-
lular physiology and cancer [2]. Furthermore, mass
spectrometry-based peptide sequencing is rapidly matur-
ing, promoting studies that provide an unbiased analysis
of information flowing from DNA to mRNA to protein
to post-translational modification without the need for
probes or antibodies at the individual gene or protein
level [3]. Finally, deregulation of histone function and
DNA methylation is readily evident in many tumor types
and is a further consideration in cancer pathogenesis [4].
There is a growing chasm between our understanding of
the breast cancer genome and our ability to translate
these insights into improved patient outcomes. In this
review, we present some of the most recent findings in
the genomics field, from the biological discoveries eman-
ating from genome sequencing studies to the clinical im-
plications of those findings and finally to the future
areas of potential research in the field.
Recent biologically relevant findings in the
genomics field
Significantly mutated genes versus background
mutations in breast cancer
Sequencing of DNA and RNA from tumors by using
massively parallel sequencing with a capture or other
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sequence selection approach (exomes or candidate
genes) or unbiased ‘whole genome’ approach has become
a standard research tool now that the technology has
been extensively commercialized [5-7]. One objective of
cancer sequencing studies is to identify genes that have
undergone somatic mutations, which contribute to ma-
lignant transformation. Genes that accumulate somatic
mutations at a higher than stochastic rate are referred to
as ‘significantly mutated genes’ (SMGs) and are consid-
ered likely drivers of malignant progression. In breast
cancer, there is a dramatic difference in the SMG list be-
tween luminal-type breast cancer and basal-like breast
cancer. In The Cancer Genome Atlas (TCGA) breast
cancer data, at least 20 SMGs were observed in luminal-
type A, eight in luminal-type B, but only three in basal-
like breast cancer (Table 1). This is not because luminal
breast cancer genomes are more complex than those of
basal-like breast cancer; in fact, the opposite is true.
Basal-like breast cancer genomes are often so complex
that it has proven difficult to identify the causal events
by using mutation recurrence statistics. Furthermore,
structural rearrangements (large-scale chromosomal de-
letions, amplifications, inversions, and translocations)
are likely to play a particularly critical role in basal-like
breast cancer, and the complete delineation of these
events requires whole genome sequencing, which is
technically demanding and expensive [8].
Detection of SMGs is complicated by the presence of
a large number of likely irrelevant mutations referred to
as ‘background mutations’ [9-11]. These occur not only
in genes irrelevant to transformation but even within the
SMGs themselves; that is, a missense mutation in a large
tumor suppressor gene cannot be assumed to be always
inactivating or cause dysfunction in the encoded protein.
Mutant allele expression determined by RNA sequen-
cing (RNA seq) is one starting point for disambiguating
biologically relevant mutations on SMGs versus irrele-
vant ones. Many mutations detected at the DNA level
are not expressed at the RNA level and thus, at least
from the gain-of-function perspective, are unlikely to be
major players in the carcinogenesis process [12]. Al-
though there are challenges left to functionalize many of
the SMGs as drivers of carcinogenesis, some progress
has been made. RNA seq is widely used for the nomin-
ation and validation of expressed fusion genes and was
recently used to define an endocrine therapy resistance-
associated ESR1 translocation [12]. Ultimately, functional
studies are critical for resolving the role of mutations in
certain SMGs versus background mutations, since the
large number of mutations requiring annotation creates
an extreme challenge, if this is done in an unbiased way
[13]. An alternative approach is to be selective and initially
study those associated with a therapeutic hypothesis.
Another priority consists of the SMGs themselves, as the
biology served by many of these, particularly those
involved in mechanisms such as histone methylation,
splicing, transcription, and long non-coding (lnc)
RNA function is unclear. For example, whole genome
analysis revealed clustered mutations in MALAT1,
suggesting a gain-of-function role for this poorly
understood and abundant lncRNA in breast cancer
[14]. The functions of luminal SMGs have particularly
striking similarities to drivers in hematopoietic malignan-
cies [14], a link also emphasized by a recent study on
the role of estradiol in hematopoiesis [15]. A particu-
larly vexing problem is the functional resolution of
mutated genes that drive pathogenesis in just a few
patients or even in only one patient. A significant
number of cases of luminal-type breast cancer in the
TCGA analysis did not harbor a single SMG [16], suggest-
ing that current genomic approaches would potentially
benefit from additional refinement.
The genomic structure of breast cancer reveals
underlying DNA repair defects
Aside from the focus on the identification of individual
genes that are repetitively disrupted in breast cancer, a
more broad-based analysis of breast cancer genome struc-
tures has led to a paradigm shift in the way we view patho-
genesis. The standard multistep model of carcinogenesis
postulates that mutations accumulate gradually, one at a
time, in a process of Darwinian selection in which individ-
ual mutant-bearing clones effectively compete with nor-
mal cells and other clones within the tumor through the
acquisition of the ability to transform, invade, metastasize,
and evade drug treatment [17]. However, it was recently
demonstrated that multiple mutations can arise over a
very short period wherein multiple chromosomal breaks
that occurred during a single catastrophic cell division
event are (rarely) viably repaired, reshuffling the genome
in a way that rapidly triggers transformation though
the simultaneous oncogene amplifications and tumor sup-
pressor gene deletions in the vicinity of the multiple trans-
locations that ensue (chromothripsis) [18] (Figure 1). The
reported frequency of chromothripsis in breast cancer var-
ies from 2% to 11.06% [18,19]. Since chromothripsis and
interval breast cancer are both marked by the suddenness
of their appearance, we hypothesize that chromothripsis
might explain the development of rapidly progressing,
so-called ‘interval’, breast cancers that arise suddenly be-
tween screening visits. For this class of tumors, screen-
ing could never be effective as the time span of tumor
development is too short. The genomic structure of
interval breast cancers should be pursued aggressively
as these tumors carry a high mortality burden. As more
patients are included in clinical trials that include longi-
tudinal genome sequencing of tumor samples, this hy-
pothesis will be tested in the near future.
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In another conceptual breakthrough, investigators at
the Sanger Institute demonstrated that there are more
than 20 different patterns of somatic mutation in cancer
based on copy number aberrations and nucleotide sub-
stitution patterns, with a subset of these recurrently ob-
served in breast cancer (APOBEC, BRCA1/2, Signature
B) [20]. Overexpression of cytidine deaminase APOBEC
family members, in particular, has come into sharp
focus. Clustered mutations characteristic of APOBEC
activity have been particularly observed in and around
chromosomal breakpoints, suggesting that single-stranded
DNA generated during aberrant DNA repair is a substrate
Table 1 Significantly mutated genes based on all luminal versus basal-like breast cancers in The Cancer Genome Atlas
dataset
Gene Luminal A (n = 225) Luminal B (n = 126) Basal-like (n = 93)
Number of cases LRT CT Number of cases LRT CT Number of cases LRT CT
TP53 28 0 0 39 0 0 74 0 0
PIK3CA 105 0 0 40 0 0 8 4.0 × 10−6 3.4 × 10−7
GATA3 32 0 0 19 0 0 2 NA NA
MAP3K1 30 0 0 6 1.7 × 10−8 4.7 × 10−7 0 NA NA
MLL3 19 1.5 × 10−10 1.7 × 10−11 7 NA NA 6 NA NA
CDH1 23 0 0 6 3.6 × 10−3 6.6 × 10−3 0 NA NA
MAP2K4 16 0 0 3 NA NA 0 NA NA
RUNX1 13 0 0 3 NA NA 0 NA NA
PTEN 9 4.3 × 10−9 1.3 × 10−11 6 3.7 × 10−6 1.9 × 10−7 1 NA NA
TBX3 6 1.0 × 10−6 2.7 × 10−5 6 9.4 × 10−5 1.4 × 10−4 1 NA NA
PIK3R1 4 NA NA 4 NA NA 2 NA NA
AKT1 8 1.4 × 10−11 3.2 × 10−9 3 NA NA 0 NA NA
CBFB 5 4.2 × 10−5 2.7 × 10−5 2 NA NA 0 NA NA
TBL1XR1 5 2.9 × 10−2 1.2 × 10−3 1 NA NA 0 NA NA
NCOR1 12 3.8 × 10−8 6.8 × 10−9 3 NA NA 2 NA NA
CTCF 9 8.8 × 10−4 3.0 × 10−6 2 NA NA 1 NA NA
ZFP36L1 2 NA NA 4 1.3 × 10−2 1.7 × 10−2 1 NA NA
GPS2 4 1.2 × 10−3 6.0 × 10−3 1 NA NA 1 NA NA
SF3B1 7 1.1 × 10−6 5.3 × 10−5 0 NA NA 1 NA NA
CDKN1B 3 5.4 × 10−3 1.9 × 10−2 1 NA NA 0 NA NA
USH2A 7 NA NA 4 NA NA 10 NA NA
RPGR 2 NA NA 2 NA NA 4 NA NA
RB1 1 NA NA 4 NA NA 4 2.5 × 10−2 4.8 × 10−2
AFF2 3 NA NA 3 NA NA 4 NA NA
NF1 6 NA NA 5 NA NA 2 NA NA
PTPN22 1 NA NA 3 NA NA 0 NA NA
RYR2 6 NA NA 10 NA NA 2 NA NA
PTPRD 4 NA NA 5 NA NA 1 NA NA
OR6A2 2 NA NA 1 NA NA 0 NA NA
HIST1H2BC 1 NA NA 1 NA NA 1 NA NA
GPR32 3 8.9 × 10−3 4.3 × 10−2 1 NA NA 1 NA NA
CLEC19A 0 NA NA 1 NA NA 0 NA NA
CCND3 2 1.5 × 10−4 1.1 × 10−3 0 NA NA 0 NA NA
SEPT13 2 NA NA 0 NA NA 1 NA NA
DCAF4L2 1 NA NA 3 NA NA 1 NA NA
CT, chemotherapy; LRT, loco-regional treatment; NA, mutations observed were not considered statistically significant.
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for APOBEC enzymatic activity [21]. Differences in DNA
repair defects explain the striking finding that some breast
cancers display many more mutations than others [20,22].
Thus, even in the absence of a known SMG, it is possible
to classify breast cancers on the basis of DNA repair de-
fects and this could be clinically relevant. For example,
clinical assays in development aim to identify tumors with
defects in homologous recombination, which sensitize tu-
mors to cytotoxic chemotherapy [23].
Intra-tumor heterogeneity in breast cancer
Chromothripsis, multistep progression, and defects in
DNA repair combine to produce astonishing levels of
both intra-tumoral and inter-tumoral heterogeneity in
breast cancer. This complexity is an obvious explanation
for the difficulty in curing breast cancer, particularly
when advanced. As the tumor progresses and dissemi-
nates, the repertoire of biological possibilities encoded
within billions of malignant cells, each subtly genetically
different, means that resistance to targeted or more trad-
itional cytotoxic therapy is almost inevitable. There is
still not enough genomic data from multiple cancer sam-
ples from the same patient to track somatic mutation
patterns from the primary through to metastatic disease
and subsequent drug resistance. Longitudinal studies of
this type, however, have been conducted successfully in
Figure 1 The presence of translocations and amplification at the ends of the breakpoints is evidence of chromothripsis in this Circos plot
from a breast cancer sample. Chromothripsis scars the genome when localized chromosome shattering and repair occur in a one-off catastrophe.
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individual cases. In 2009, Shah and colleagues [24] de-
scribed the mutational evolution of a lobular breast car-
cinoma by using next-generation sequencing. Out of the
32 somatic, protein-coding mutations present in the me-
tastasis, 19 could not be detected in the primary, five
were prevalent in the primary, and six were present in
the primary with a lower frequency. The Washington
University group investigated the progression of a breast
cancer to the brain at the whole genome level and found
that the primary tumor and metastasis harbored approxi-
mately 48 somatic, protein-coding mutations [8]. In the
metastatic sample, there were few de novo mutations, but
higher variant allele frequencies and a few much lower,
supporting a ‘clonal remodeling’ hypothesis for metastatic
spread. At the single cell level of the tumor, various tech-
niques have been used to directly visualize and quantify
chromosomal aberrations, including duplications, dele-
tions, and other distinctive chromosomal rearrangements.
These studies show that breast cancers routinely exhibit
genetic heterogeneity at preferred loci [25-29].
Evidence for marked tumor heterogeneity can be
found in studies of other cancer types. For example, in a
study of a renal cancer with metastasis to the lung and
in the chest wall, sequencing of the metastases and nine
different areas within the primary tumor found that only
a third of mutations were common to all samples [30].
Based on these data, we can infer that heterogeneity and
different subclones develop within the primary tumor,
not all of which have the same metastatic potential. Me-
tastases can develop early or late in each cancer’s evolu-
tionary history and are products of ongoing clonal
evolution, which can be slow or very rapid. The ability
to sequence individual cancer cells [31] will further illu-
minate this issue, although the complexity of the data
analysis remains a considerable challenge.
Clinical implications of genomic discoveries
Clinical translation of massively parallel sequencing of
DNA in breast cancer
The sequencing of cancer with data return to the patient
and physician is being piloted through ‘genomic tumor
boards’ [32]. However, the complexity of the breast can-
cer genome has slowed progress, as has the relative pau-
city of obvious drug mutation matches [33]. Unlike drug
therapy matched somatic mutations to melanoma and
non-small cell lung cancer, drug therapy matched to the
presence of a somatic mutation has yet to be robustly
established as a standard approach in breast cancer.
A number of strategies to increase the productivity
and ‘translatability’ of DNA, RNA, and peptide sequen-
cing studies in breast cancer should be considered. The
initial set of sequencing-based studies in breast cancer
revealed that this is one of the most heterogeneous
forms of cancer, with the four commonly accepted subtypes
(luminal-type A, luminal-type B, HER2-enriched, and
basal-like) displaying distinct somatic mutation, gene
copy, and epigenetic profiles [16]. Within the next few
years, tens of thousands of primary breast cancers will
likely be sequenced but often through clinical sequen-
cing programs without a current systematic and broad-
based plan to integrate the data with clinical endpoints.
These studies risk following the course of the TCGA
breast cancer study. While a technical tour de force,
TCGA was largely a cross-platform genome-cataloging
exercise and not a systematic clinical research address-
ing a particular problem in oncology [16]. Thus, it will
not be possible to link the TCGA data to important
clinical phenotypes such as drug response. Since poly-
pharmacy is the rule in breast cancer treatment, estab-
lishing a link between mutational events and the
efficacy of individual drugs is impossible unless a dedi-
cated study is conducted. The neoadjuvant treatment
setting allows ethical treatment plans with single agents
as well as the acquisition of serial samples to assess the
effect of treatment on breast cancer somatic genomes -
another subject in its infancy in breast cancer. Thus, a
systematic approach linking high-quality sample acqui-
sition, uniform neoadjuvant therapy regimens, and inte-
grated ‘omics’ should be a high priority for clinical
investigators. An example is provided by an integrated
analysis of whole genome, exome-based somatic mutation
detection, gene-expression, and gene copy profiles that
identified molecular correlates of aromatase inhibitor-
resistant proliferation by using samples from a neoadju-
vant study [14]. Mutations in TP53 were associated with
endocrine therapy resistance, poor prognosis luminal-type
B features, mutations in the stress kinase MAP3K1 with
low proliferation and luminal-type A features, and mu-
tations in GATA3 with increased responsiveness to
aromatase inhibition. A current research focus is to con-
firm these findings and to conduct additional studies with
large sample sizes to link other breast cancer SMGs to
clinical outcomes.
The druggable breast cancer genome
A major obstacle to the translation of newly defined
genetic alterations into clinical benefit for patients lies
in the identification of biologically relevant druggable
aberrations that can be used as therapeutic targets [34].
To address this goal, programs such as dGene [35] and
DGIdb [36] have been developed. The dGene program is
an updated version of the druggable genome concept
introduced in 2002 by Hopkins and Groom [37]. The
druggable genome refers to a subset of genes that are
known or predicted to interact with drugs. The software
stratifies mutations from any database containing gene
symbols into 10 different gene classes that are both
potentially druggable and clinically relevant to cancer
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biology. An annotation and filtering tool is used to
prioritize mutations for consideration. The analysis of a
recent breast cancer genomic study [14] highlights the
potential utility of this approach. From a total of 2,622
single-nucleotide variants identified in the neoadjuvant
aromatase inhibitor discussed above, dGene identified
368 mutations out of 2,622 single-nucleotide variants as
occurring in 255 druggable genes. When filtered for re-
currence, that number was narrowed to 37 potentially
druggable mutated genes present in at least two patients
(Table 2). Despite its utility, dGene does not provide in-
formation on the type of mutation or guarantee clinical
pertinence of mutations associated with any specific
gene. This underscores the critical need to functionally
test these and other genomic results.
A similar tool is DGIdb [36]. The concept behind the
DGIdb is to classify gene mutations into two classes:
genes that are known to have drug interactions and
genes that are potentially druggable according to their
gene category. DGIdb was developed by integrating data
from 13 different sources and contains over 14,000
drug-gene interactions. It also includes 6,761 genes that
belong to one or more of 39 potentially druggable gene
categories. The utility of DGIdb was demonstrated by
analyzing a cohort of 1,273 patients who were included
in whole-genome or exome sequencing studies
[16,38-41]. The software identified 6 of 31 genes (AKT1,
CDH1, LRP2, PIK3CA, RYR2, and TP53) that were re-
currently mutated in at least 2.5% of patients and also
have known drug-gene interactions. With the addition
of the top 1% of recurring mutations, the number of
genes increased to 315. Six sources - DrugBank, MyCan-
cerGenome, the Pharmacogenetics Knowledge Base
(PharmGKB), Trends in the Exploitation of Novel Drug
Targets (TEND), Targeted Agents in Lung Cancer
(TALC), and Therapeutic Target Database (TTD) - were
interrogated by DGldb to identify a total of 354 possible
druggable gene interactions among the 315 genes. There
was limited overlap between the sources, and only one
drug-gene interaction was present in all six sources sim-
ultaneously (Figure 2a). The nature and extent of cur-
ation as well as the overall methodologies employed by
each source are different (Figure 2a), which explains the
limited overlap between the different sources. Some of
the 315 genes are in potentially druggable categories
(dGene), and others represent opportunities for drug
discovery (Figure 2b).
This analysis serves to emphasize that these druggable
genome approaches remain unvalidated by clinical trials
and the pre-existing pharmacopeia is obviously inad-
equate, although ‘drug repurposing’ - the concept of
redirecting US Food and Drug Administration-approved
drugs to new secondary indications - is clearly an oppor-
tunity. Thus, in their current form, these computational
approaches are mostly hypothesis-generating tools that
are intended to accelerate medical research, not tools for
clinical action (at least not yet). The next logical step
after using such tools is to design functional studies to
test the related drugs and find a more reliable answer as
to whether such mutations are drivers of carcinogenesis
or just background mutations.
HER2 and ESR1 mutations as examples of novel
druggable targets
The utility of detailed preclinical work on potentially
druggable genes is nicely illustrated by the study of
HER2 mutations in breast cancer. Data from eight breast
cancer genome-sequencing studies identified 25 patients
with HER2 somatic mutations without HER2 amplifica-
tion [14,16,24,38-42]. Thirteen HER2 mutations were
functionally characterized by using in vitro kinase assays,
protein structure analysis, cell culture, and xenograft ex-
periments [43]. The results showed that the investiga-
tional drug neratinib, an irreversible HER2 inhibitor,
rather than lapatinib, an approved HER2 kinase inhibi-
tor, was a better approach for clinical studies since some
of the recurrent mutations were naturally lapatinib-
resistant. This is a result that simple drug somatic muta-
tion matching software would not have revealed. Cur-
rently, patients with advanced HER2 mutation-positive
tumors are being enrolled into a single-agent study of
neratinib (NCT01670877). Point mutations in the
estradiol-binding domain of the estrogen receptor gene
(ESR1) are emerging as a potent cause of acquired endo-
crine therapy resistance. Although there are no drugs
that specifically target these mutations, alternative endo-
crine therapies may be effective in this setting [44,45]
and this possibility will soon be addressed in clinical
trials.
Patient-derived xenografts as genomic models for breast
cancer
A major criticism of standard cell lines as a model for
human breast cancer is that they are essentially discon-
nected from the individuals from whom they were de-
rived. Without knowledge of the progenitor tumor
genome as a reference point and no knowledge of the
clinical characteristics of the patient who donated the
tissue, it is uncertain what the cell lines actually model
from an individual patient perspective and to what de-
gree genetic drift has occurred after prolonged in vitro
culture. These limitations likely contribute to the poor
predictive utility of cell line panels in drug development
[46-48]. An alternative preclinical model for drug
optimization and target validation is the patient-derived
xenograft (PDX) approach. Detailed information covering
the continuum from specimen acquisition to development
of patient-derived xenografts has been presented and
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reviewed elsewhere [8,49-52]. In brief, a biopsy-sized
sample of primary or metastatic tumor is transferred
directly into an immunodeficient mouse by orthotopic
or subcutaneous implantation. Once tumor engraftment
has occurred, RNA and DNA sequencing or chip-based
analysis is employed to compare the patient tumor to the
PDX. PDXs maintain fidelity to the patient tumor based
on molecular subtypes, mutational spectrum, copy num-
ber variations, gene expression profiles, and histopath-
ology [50,53-56]. PDX models faithfully recapitulate the
Table 2 Categorization of single-nucleotide variants in 77 breast cancer tumors using dGene: 37 dGene entries present
in at least 2 out of 77 samples, organized by class and patients affected
NCBI symbol Full name dGene class Patients affected
CASR Calcium-sensing receptor G protein-coupled receptor 3
GPR112 G protein-coupled receptor 112 G protein-coupled receptor 3
AGTR2 Angiotensin II receptor, type 2 G protein-coupled receptor 2
MC5R Melanocortin 5 receptor G protein-coupled receptor 2
OR2L2 Olfactory receptor, family 2, subfamily L, member 2 G protein-coupled receptor 2
OR51B5 Olfactory receptor, family 51, subfamily B, member 5 G protein-coupled receptor 2
PIK3CA Phosphoinositide-3-kinase, catalytic, alpha polypeptide PI3K 37
BIRC6 Baculoviral IAP repeat containing 6 Proteinase inhibitor 4
CPAMD8 C3 and PZP-like, α-2-macroglobulin domain containing 8 Proteinase inhibitor 3
COL28A1 Collagen, type XXVIII, alpha 1 Proteinase inhibitor 2
COL6A3 Collagen, type VI, alpha 3 Proteinase inhibitor 2
AGBL1 ATP/GTP binding protein-like 1 Protease 2
CPVL Carboxypeptidase, vitellogenic-like Protease 2
PCSK5 Proprotein convertase subtilisin/kexin type 5 Protease 2
RELN Reelin Protease 2
SENP7 SUMO1/sentrin specific peptidase 7 Protease 2
USP9X Ubiquitin specific peptidase 9, X-linked Protease 2
PTPRF Protein tyrosine phosphatase, receptor type, F Phosphatase 2
PTPRU Protein tyrosine phosphatase, receptor type, U Phosphatase 2
SSH3 Slingshot homolog 3 (Drosophila) Phosohatase 2
MAP3K1 Mitogen-activated protein kinase kinase kinase 1 Serine theonine kinase 9
TTN Titin Serine theonine kinase 6
ATR Ataxia telangiectasia and Rad3 related Serine theonine kinase 5
OBSCN Obscurin Serine theonine kinase 3
SMG1 Smg-1 homolog Serine theonine kinase 3
ALPK2 Alpha-kinase 2 Serine theonine kinase 2
BRAF V-raf murine sarcoma viral oncogene homolog B1 Serine theonine kinase 2
DCLK3 Doublecortin-like kinase 3 Serine theonine kinase 2
LRRK2 Leucine-rich repeat kinase 2 Serine theonine kinase 2
MAP2K4 Mitogen-activated protein kinase kinase 4 Serine theonine kinase 2
TAF1L TATA box binding protein (TBP)-associated factor Serine theonine kinase 2
TBK1 TANK-binding kinase 1 Serine theonine kinase 2
ULK4 Unc-51-like kinase 4 Serine theonine kinase 2
INSRR Insulin receptor-related receptor Tyrosine kinase 3
KIT C-kit Tyrosine kinase 2
PDGFRA Platelet-derived growth factor receptor Tyrosine kinase 2
TEX14 Testis expressed 14 Tyrosine kinase 2
NCBI, National Center for Biotechnology Information.
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Figure 2 Druggability of significantly mutated gene (SMG) in breast cancer. (a) Overlap between six sources that generated a list of 354 possible
drug-gene interactions among 315 genes recurrently mutated in breast cancer patients and analyzed by DGIdb. One hundred and seventy-six drug-gene
interactions were identified by DrugBank, 87 by MyCancerGenome, 77 by Therapeutic Target Database (TTD), 71 by Trends in the Exploitation of Novel
Drug Targets (TEND), 49 by Targeted Agents in Lung Cancer (TALC), and 44 by the Pharmacogenetics Knowledge Base (PharmGKB). (b) Distribution of
315 genes in potentially druggable categories (from dGene) and the numbers of genes in these categories that are targeted by a known drug.
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intra-tumor heterogeneity and response to chemotherapy
[53]. This close resemblance between the PDXs and the
patient tumor makes it a suitable predictive preclinical
model. The deployment of PDXs therefore can be consid-
ered a ‘test bed’ for personalized precision medicine in
which genome-forward hypotheses can be assessed pre-
clinically. However, despite the great promise and utility
of PDXs, there are some drawbacks that need to be
resolved to ensure wider adoption and improved utility.
The limitations are the higher comparative cost, high level
of technical expertise needed, the lack of an immune
system, the effect of differences between the mouse and
human microenvironment, and the degree of genetic drift
and how this affects conclusions regarding biological and
pharmacological findings.
Even with the mentioned limitations, the PDX model
has great utility in breast cancer research. Through the
genome sequencing of different PDX lines, Li and col-
leagues [12] identified new ESR1 point mutations and
translocations. These gene mutations and the ESR1-YAP1
gene fusion were further investigated through functional
studies that directly implicated them in resistance to treat-
ment. Not coincidentally, the patients from whom these
PDXs were derived presented with endocrine treatment
resistance during their course of treatment.
Future areas of research
Proteomics as the next step in the annotation of the
breast cancer genome
A fundamental problem in the study of cancer genomics
at the level of DNA and RNA is that conclusions regard-
ing pathway activation are indirect since proteins, not
nucleic acids, execute these functions. Thus, when sig-
naling and biology are discussed, it is through inference
from signal transduction databases that may or may
not have been conducted in the relevant biological
context and that may or may not be correct. Informatics
approaches generate hypotheses, not conclusions [57,58].
The reverse phase protein array (RPPA) is one answer
to the problem of efficiently tracking protein levels and
phosphorylation events [59]. Here, tumor protein ex-
tracts from many tumors are spotted into slides and
probed with highly quality-controlled antibodies. Unfor-
tunately, the generation of RPPA-quality antibodies is
technically challenging; in particular, the number of
phosphosite-specific antibodies is very limited. There-
fore, mass spectrometry is being developed to examine
the protein biochemistry of the cancer cells in less
biased ways by direct protein sequencing and mass ana-
lysis to determine post-translational modifications [3].
Next-generation proteomic technologies are poised to
provide deep information on tumor proteomes and on
post-translational modifications of all types. When com-
bined with genomic data, proteomics may enable a deeper
understanding of complex mechanisms that regulate gene
function and dysfunction in cancer. These objectives are
being realized by the National Cancer Institute Clinical
Proteomic Tumor Analysis Consortium, which is applying
standardized proteome analysis platforms to analyze
tumor tissues from the TCGA program as well as unique
cell and xenograft models and other tissue collections, all
of which are accompanied by rich genomic datasets [60].
Conclusions
The expansion of knowledge in genomics is already having
a profound effect on breast cancer research and increas-
ingly on treatment. It is clear, however, that genome-
sequencing studies have still not been adequately designed
to address specific questions in breast cancer oncology.
This is essential to translate the comprehensive catalog of
recurrent mutations in breast cancer to a functionally and
pharmacologically annotated treatment road map. Through
the sequencing of tumors in different time-points, we will
be able to identify cellular pathways and targets for drug
development and use this information for the development
of clinically testable hypotheses. Integrated approaches that
not only account for DNA and RNA aberrations but also
document protein function and biochemistry are clearly the
next technical horizon [60].
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